Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) and PD-1 Blockade, With Targeted Ablation of Resistant Lesions, in Patients With Non-Castrate Recurrent Oligometastatic Prostate Cancer

NCT07090148 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.

NCT NCT07090148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07090148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) and PD-1 Blockade, With Targeted Ablation of Resistant Lesions, in Patients With Non-Castrate Recurrent Oligometastatic Prostate Cancer
Lead sponsor
University of Wisconsin, Madison
Phase
Phase 1
Overall status
Recruiting
Start date
March 3, 2026
Completion date
October 31, 2030
Enrollment
14 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-castrate prostate cancer, oligometastatic prostate cancer (ompc), prostate cancer patients, recurrent prostate cancer